Business Wire

LFB

25.7.2022 16:37:08 CEST | Business Wire | Press release

Share
LFB Announces the Approval of CEVENFACTA® (eptacog beta) in the European Union

LFB today announced that the European Medicines Agency (EMA) has granted on July 15th a Marketing Authorisation for CEVENFACTA® (eptacog beta), as the first new bypassing agent in over 20 years. CEVENFACTA® is indicated in adults and adolescents (12 years of age and older) for the treatment of bleeding episodes and for the prevention of bleeding in those undergoing surgery or invasive procedures in the following patient groups:

  • in patients with congenital haemophilia with high-responding inhibitors to coagulation factors VIII or IX (i.e. ≥5 Bethesda Units (BU));
  • in patients with congenital haemophilia with low titre inhibitors (BU <5), but expected to have a high anamnestic response to factor VIII or factor IX administration or expected to be refractory to increased dosing of FVIII or FIX.

Denis Delval, LFB’s Chairman and Chief Executive Officer, stated: “We are very pleased with the approval of CEVENFACTA ® by the EMA, which provides a new treatment option for haemophilia patients with inhibitors in the European Union. This approval is a validation of our innovative LFB technology and the acknowledgement of LFB’s deep commitment to patients.”

Dr. Patrick Delavault, MD, LFB’s Executive Vice President Scientific, Medical and Regulatory Affairs, stated: “We need to keep in mind constantly what a bleeding event, even a single bleeding event, means to a haemophilia patient with inhibitors and to his family. This novel treatment alternative is a significative opportunity to improve patients’ lives”.

LFB has been granted a Marketing Authorisation for SEVENFACT® (eptacog beta) in Mexico on June 2nd for the treatment of bleeding episodes in adults and adolescents with haemophilia A or B with inhibitors.

About PERSEPT studies:

The approval of CEVENFACTA® was based on data from the phase III clinical trials, PERSEPT 1 and PERSEPT 3.

The PERSEPT 1 Phase III , multicentre, randomised, open-label crossover study of two initial dose regimens (75µg/kg and 225µg/kg), evaluated 468 bleeding episodes across the full type of severity of bleeding episodes (mild, moderate, and severe), in 27 adolescent and adult haemophilia A and B patients with inhibitors (12-54 years of age). Both dosing regimens met the primary endpoint with 81% and 90% of bleeds controlled at 12 hours with the 75µg/kg dose and the 225µg/kg dose respectively. By 24 hours, haemostatic efficacy (secondary endpoint) was retained in 96.7% of bleeding episodes treated with the 75 µg/kg dose regimen and 99.5% of redundancy bleeding episodes treated with the 225 µg/kg dose, without requiring any alternative therapy. The median time to attain haemostatic efficacy was 5.98 hours for the 75 µg/kg dosing regimen and 3 hours for the 225 µg/kg dosing regimen. A median of 2 injections was needed to treat a bleeding episode with the 75 µg/kg and a median of only 1 injection of the 225 µg/kg dosing regimen was needed.

The PERSEPT 3 Phase III , multicentre, open-label, single-arm study evaluated the safety and efficacy of CEVENFACTA® in haemophilia A or B patients with inhibitors who were scheduled for an elective surgical or other invasive procedure. 12 patients were enrolled in the study, 6 with minor procedures and 6 with major procedures. For major surgical/invasive procedures, treatment was administered at an initial bolus dose of 200 µg/kg immediately before the start of the invasive procedure. For a minor elective surgical procedure, an initial bolus dose of 75 µg/kg was administered immediately before the start of the procedure. Overall, 81.8% of procedures were reported as successfully treated at 48 hours after the last administration of the product.

No thromboembolic events were reported in these two clinical trials. No Serious Adverse Events (SAEs) were considered as related to the treatment.

Patients should be monitored for any signs of thrombosis, hypersensitivity and neutralising antibodies. The most frequently reported adverse reactions in studies were infusion site discomfort, infusion site haematoma, post-procedural haematoma, infusion related reaction, increased body temperature, dizziness and headache.

About LFB

LFB is a bio-pharmaceutical group that develops, manufactures and markets plasma derived products and recombinant proteins for the treatment of patients with serious and often rare diseases. LFB was founded in 1994 in France and is among the leading European bio-pharmaceutical companies providing mainly hospital-based healthcare professionals with blood-derived therapeutics with the vision to provide treatment options to patients in three major areas: immunology, haemostasis, and intensive care.

LFB currently markets 15 biomedicinal products in more than 30 countries.

Please visit www.groupe-lfb.com for further information on LFB.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Xsolla Launches Quest Builder and Backpack, Enabling Video Game Developers to Reward Players With Items to Collect, Own, and Give Away17.11.2026 15:00:00 CET | Press release

Xsolla Expands Its Core Platform With Xsolla Quest Builder and Backpack to Help Developers and Brands Use Digital Items to Attract and Retain Players Xsolla (USA), Inc., a global commerce company, today announced the launch of Xsolla Quest Builder, a no-code tool that lets video game developers reward players with digital items for reaching goals tracked through game events, alongside Xsolla Backpack, a persistent inventory where players keep those items. Xsolla Quest Builder helps developers acquire new users, improve retention and lifetime value, and learn what players value and want in their games. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117128292/en/ Graphic: Xsolla Across the industry, players want more value from games and the digital items they acquire to enhance their in-game experience. To address this, along with rising user acquisition costs facing game developers, Xsolla is introducing a new way for pla

Trulioo’s Global Risk Platform Unlocks Device and Behavioral Intelligence Via Bureau Partnership17.11.2026 15:00:00 CET | Press release

Trulioo customers can now verify identities and assess fraud risk in one integrated platform Trulioo and Bureau today announced a joint go-to-market partnership that adds Bureau’s device and behavioral intelligence, alongside its proprietary cross-business network graph intelligence for identifying connected fraud activity, to Trulioo’s global risk intelligence platform for fraud and financial crimes. Together, the companies are helping banks, fintechs, payments companies and marketplaces in APAC and the U.S. confirm who someone is and assess whether to trust them, all on one platform. AI is making fraud more complex and harder to detect, and organizations need stronger defenses to keep pace. Identity verification is only part of the picture; businesses also need to understand the risk behind every interaction, from onboarding throughout the customer journey. By partnering with Bureau, Trulioo is adding device and behavioral intelligence to its identity verification and risk signals, c

Phison Launches Purpose-Built Storage Solutions for New Space Economy17.11.2026 15:00:00 CET | Press release

New purpose-built Pascari Space storage solutions deliver mission-specific reliability, resilience and customization for spacecraft, lunar and orbital data centers Supercomputing 2026 (SC26) – Phison Electronics (TW:8299TT), a global leader in NAND flash storage solutions, today announced the launch of Pascari Space, a new category of purpose-built SSD solutions engineered for commercial outer space applications and orbital infrastructure, on display this week at the SC26 conference. Built upon Phison's decades of NAND engineering expertise and flight-proven storage heritage, Pascari Space leverages Phison IMAGIN+ customization and design services to deliver mission-specific storage solutions built to withstand the extreme demands of outer space. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117623865/en/ Phison Launches Purpose-Built Storage Solutions for New Space Economy As terrestrial data infrastructure faces mounti

Phison AI Data Platform Brings Sovereign, On-Premises Generative BI to Enterprises17.11.2026 15:00:00 CET | Press release

Turnkey system combines high-performance private AI inference, generative business intelligence and persistent enterprise storage for operational resilience Supercomputing 2026 (SC26) – Phison Electronics (TW:8299TT), a global leader in NAND flash storage solutions, today announced the launch of the Phison AI Data Platform (AIDP) with generative business intelligence (GenBI), a turnkey, sovereign AI system that will be showcased at Supercomputing 2026 (SC26) in booth #5413. Powered by Pascari aiDAPTIV ™ Cache Memory technology, Phison AIDP combines locally hosted AI models, integrated inference services, governed analytics and persistent enterprise storage to help organizations unlock business intelligence while maintaining control over their data, infrastructure and AI operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117045294/en/ Phison AI Data Platform Brings Sovereign, On-Premises Generative BI to Enterprise

IQM unveils Halocene upgrade program at SC26, creating a path to over 1,000 qubits while accelerating integration with AI-based applications17.11.2026 15:00:00 CET | Press release

IQM Halocene, the company’s error-correction product line, now offers an upgrade path to over 1,000 qubits on the way to fault-tolerant quantum computing Built on IQM’s experience integrating and upgrading more quantum computers in HPC centers than any other company IQM’s HPC integration service, included with each upgrade, connects every new Halocene system to a center’s existing infrastructure, schedulers and GPU platforms, so it is productive from day one Upgrades without downtime, more value from each upgrade and continuity of software, workflows and skills from one system to the next New customers can start now and grow with Halocene, while existing customers can move to each new system seamlessly IQM Quantum Computers (Nasdaq: IQMX), a global leader in integrated quantum computing, today announced an upgrade program for IQM Halocene, its error-correction product line, that gives customers a path from the 150-qubit system of today to the over 1,000-qubit system of the future. Cust

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye